{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:12:21Z","timestamp":1776309141231,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11901-7","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:19:58Z","timestamp":1762874398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The quantity and severity of adverse drug reactions experienced by patients with multi-drug resistant tuberculosis in the Ugu District"],"prefix":"10.1186","volume":"25","author":[{"given":"Serisha","family":"Ramasir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frasia","family":"Oosthuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Bangalee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"12","key":"11901_CR1","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.7196\/samj.2020.v110i12.14721","volume":"110","author":"J Jones","year":"2020","unstructured":"Jones J, Swart A, Tommy E, Cohen K, Stewart A, Voget J, et al. Adverse drug reactions were reported to a provincial public health sector pharmacovigilance programme in South Africa. S Afr Med J. 2020;110(12):1226. https:\/\/doi.org\/10.7196\/samj.2020.v110i12.14721.","journal-title":"S Afr Med J"},{"key":"11901_CR2","unstructured":"WHO. The end TB strategy.\u00a0www.who.int. 2015. Available at: https:\/\/www.who.int\/publications\/i\/item\/WHO-HTM-TB-2015.19. Accessed 14 June 2024."},{"key":"11901_CR3","doi-asserted-by":"publisher","unstructured":"Allu\u00e9-Guardia A, Garc\u00eda JI, Torrelles JB. Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front Microbiol. 2021;12. https:\/\/doi.org\/10.3389\/fmicb.2021.612675.","DOI":"10.3389\/fmicb.2021.612675"},{"issue":"9","key":"11901_CR4","doi-asserted-by":"publisher","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","volume":"5","author":"KJ Seung","year":"2015","unstructured":"Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9):a017863. https:\/\/doi.org\/10.1101\/cshperspect.a017863.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"11901_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4197-7","author":"J Jones","year":"2019","unstructured":"Jones J, Mudaly V, Voget J, Naledi T, Maartens G, Cohen K. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases. BMC Infect Dis. 2019. https:\/\/doi.org\/10.1186\/s12879-019-4197-7.","journal-title":"BMC Infect Dis"},{"key":"11901_CR6","unstructured":"World Health Organisation. Active TB drug-safety monitoring and management (aDSM). 2024. Available at: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/diagnosis-treatment\/treatment-of-drug-resistant-tb\/active-tb-drug-safety-monitoring-and-management-(adsm). Accessed 30 May 2024."},{"key":"11901_CR7","unstructured":"www.who.int. Active TB Drug Safety Monitoring and Management (aDSM) global database: Outcome of the assessment and future of data reporting. 2021. Available at: https:\/\/www.who.int\/news\/item\/06-07-2021-active-tb-drug-safety-monitoring-and-management-(adsm)-global-database-outcome-of-the-assessment-and-future-of-data-reporting#:~:text=The%20aDSM%20framework%20has%20been. Accessed 10 May 2023."},{"issue":"6","key":"11901_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.4103\/0970-2113.217569","volume":"34","author":"A Dela","year":"2017","unstructured":"Dela A, Tank NK, Singh A, Piparva K. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: a four year retrospective study. Lung India. 2017;34(6):522. https:\/\/doi.org\/10.4103\/0970-2113.217569.","journal-title":"Lung India"},{"key":"11901_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s0924-977x(03)00097-x","volume":"13","author":"SP Roose","year":"2003","unstructured":"Roose SP. Compliance: the impact of adverse events and tolerability on the physician\u2019s treatment decisions. Eur Neuropsychopharmacol. 2003;13:85\u201392. https:\/\/doi.org\/10.1016\/s0924-977x(03)00097-x.","journal-title":"Eur Neuropsychopharmacol"},{"key":"11901_CR10","doi-asserted-by":"publisher","first-page":"205031211769040","DOI":"10.1177\/2050312117690404","volume":"5","author":"G hRt","year":"2017","unstructured":"hRt G, Stoimenova A, Dimitrova M, Kamusheva M, Petrova D, Georgiev O. Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy. SAGE Open Medicine. 2017;5:205031211769040. https:\/\/doi.org\/10.1177\/2050312117690404.","journal-title":"SAGE Open Medicine."},{"key":"11901_CR11","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. 2012. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/. Accessed on 27 June 2023."},{"issue":"9","key":"11901_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/s2213-2600(18)30235-2","volume":"6","author":"K Schnippel","year":"2018","unstructured":"Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699\u2013706. https:\/\/doi.org\/10.1016\/s2213-2600(18)30235-2.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"11901_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/nejmoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723\u201332. https:\/\/doi.org\/10.1056\/nejmoa1313865.","journal-title":"N Engl J Med"},{"key":"11901_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)02078-5","author":"RL Goodall","year":"2022","unstructured":"Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet. 2022. https:\/\/doi.org\/10.1016\/s0140-6736(22)02078-5.","journal-title":"Lancet"},{"issue":"4","key":"11901_CR15","doi-asserted-by":"publisher","first-page":"106939","DOI":"10.1016\/j.ijantimicag.2023.106939","volume":"62","author":"Y Jin","year":"2023","unstructured":"Jin Y, Benkeser D, Kipiani M, Maranchick NF, Mikiashvili L, Barbakadze K, et al. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation. Int J Antimicrob Agents. 2023;62(4):106939. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106939.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"11901_CR16","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.ijtb.2020.09.027","volume":"67","author":"A Gupta","year":"2020","unstructured":"Gupta A, Kumar V, Natarajan S, Singla R. Adverse drug reactions & drug interactions in MDR-TB patients. Indian J Tuberc. 2020;67(4):S69\u201378. https:\/\/doi.org\/10.1016\/j.ijtb.2020.09.027.","journal-title":"Indian J Tuberc"},{"key":"11901_CR17","doi-asserted-by":"publisher","unstructured":"Quiroz-Aldave JE,\u00a0Durand-V\u00e1squez MD, Gamarra-Osorio ER, Concepci\u00f3n-Urteaga LA, Pecho-Silva S, Rodr\u00edguez-Hidalgo LA, Concepci\u00f3n-Zavaleta MJ. Drug-induced hypothyroidism in tuberculosis. Expert Rev Endocrinol Metab. 2024:1\u20138. https:\/\/doi.org\/10.1080\/17446651.2024.2307525.","DOI":"10.1080\/17446651.2024.2307525"},{"key":"11901_CR18","doi-asserted-by":"publisher","first-page":"205031212311713","DOI":"10.1177\/20503121231171350","volume":"11","author":"O Kushemererwa","year":"2023","unstructured":"Kushemererwa O, Nuwagira E, Kiptoo J, Yadesa TM. Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital. Uganda. 2023;11:205031212311713\u2013205031212311713. https:\/\/doi.org\/10.1177\/20503121231171350.","journal-title":"Uganda."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11901-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11901-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11901-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:20:01Z","timestamp":1762874401000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11901-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11901"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11901-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1540"}}